CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

208700Orig1s000

Trade Name: Lutathera injection for intravenous use, 370 MBq/mL

Generic or Proper

Name:

lutetium Lu 177 dotatate

Sponsor: Advanced Accelerator Applications USA, Inc.

Approval Date: January 26, 2018

Indication: For the treatment of somatostatin receptor positive GEP-

NETs including foregut, midgut, and hindgut

neuroendocrine tumors in adults.



CENTER FOR DRUG EVALUATION AND RESEARCH

208700Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	X
Labeling	X
REMS	
Officer/Employee List	X
Multidiscipline Review(s)	X
• Summary Review	
Office Director	
• Cross Discipline Team Leader	
• Clinical	
• Non-Clinical	
• Statistical	
Clinical Pharmacology	
Product Quality Review(s)	X
Clinical Microbiology / Virology Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	X
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X



CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

208700Orig1s000

APPROVAL LETTER





Food and Drug Administration Silver Spring MD 20993

NDA 208700

NDA APPROVAL

Advanced Accelerator Applications USA, Inc. Attention: Victor Paulus, Ph.D. Global Head, Regulatory Affairs 350 Fifth Avenue, Suite 6902 New York, NY 10118

Dear Dr. Paulus:

Please refer to your New Drug Application (NDA) submitted and received April 28, 2016, and your amendments, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Lutathera (lutetium Lu 177 dotatate), injection for intravenous use, 370 MBq/mL. We also refer to our December 19, 2016, action letter regarding the application.

We acknowledge receipt of your amendment dated July 26, 2017, which constituted a complete response to our December 19, 2016, action letter.

This new drug application provides for the use of Lutathera (lutetium Lu 177 dotatate) injection for intravenous use, 370 MBq/mL for the treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults.

APPROVAL

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the prescribing information,



Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the carton and immediate container labels submitted on January 22, 2018, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format*—

Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3). For administrative purposes, designate this submission "Final Printed Carton and Container Labels for approved NDA 208700." Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

The dating period for Lutathera shall be 72 hours post calibration, defined as when stored below 25 °C (77°C).

ADVISORY COMMITTEE

Your application for lutetium Lu 177 dotatate was not referred to an FDA advisory committee because there were no public health issues raised that would benefit from a public discussion or that required the expert opinions of the Committee. In addition, the safety profile of the drug is deemed acceptable for the indicated population of patients.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

